Skip to content
Research/Cognitive Enhancement/Istradefylline

Istradefylline

Istradefylline is an adenosine A2A receptor antagonist primarily used as an adjunctive treatment for Parkinson's disease to improve motor function. By modulating adenosine pathways, it may offer cognitive benefits and neuroprotection, which are relevant for longevity and health optimization.

Intelligence Profile

Research Papers

Research on istradefylline, primarily an adenosine A2A receptor antagonist, includes several important studies and clinical trials examining its effects and applications. Here’s a summary:

  1. Mechanistic Studies:

    • A study published in Scientific Reports explored the electronic structures of istradefylline using advanced modeling techniques. This research aimed to understand the drug's interaction at a molecular level, potentially influencing neuronal excitability (PMID: 42350597).

  2. Clinical Research in Parkinson's Disease (PD):

    • A study in Purinergic Signalling highlighted istradefylline's dual role in improving motor and cognitive outcomes in PD, showcasing its potential beyond merely addressing movement disorders (PMID: 42133141).
    • A pilot study in Frontiers in Neurology utilized functional MRI to observe neural activity changes in PD patients undergoing istradefylline treatment. This study was part of a broader investigation that included hybrid assistive technologies, aiming to enhance therapeutic outcomes (PMID: 42222535).

  3. Pharmacokinetics and Safety:

    • The clinical trial NCT02174250 assessed how rifampin affected istradefylline metabolism in healthy volunteers. This Phase 1 trial established some metabolic interactions, crucial for understanding how it may be co-administered with other drugs.
    • Another completed Phase 1 trial, NCT02256033, assessed istradefylline's pharmacokinetics in individuals with mild hepatic impairment, informing dosing practices in this population.

  4. Long-term and Combination Therapies:

    • The long-term safety and efficacy of istradefylline in PD patients were evaluated in a completed Phase 3 trial (NCT02610231), providing critical information on its prolonged use in managing moderate to severe PD symptoms.
    • An upcoming study (NCT05217498) aims to investigate combining istradefylline with low oxygen therapy to enhance mobility after spinal cord injury, indicating a potential for expanding its use beyond PD.

These studies and trials indicate istradefylline's multifaceted role both in clinical settings and its potential as part of combination therapies. However, further research is ongoing to refine its application across different conditions.

Disclaimer: This information is intended for educational purposes and should not be used as a substitute for professional medical advice.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.